C WorldWide Group Holding A S Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX)

C WorldWide Group Holding A S bought a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 445,838 shares of the biopharmaceutical company's stock, valued at approximately $13,879,000. C WorldWide Group Holding A S owned approximately 0.08% of Royalty Pharma at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in RPRX. Louisbourg Investments Inc. acquired a new position in shares of Royalty Pharma during the first quarter valued at approximately $28,000. MassMutual Private Wealth & Trust FSB boosted its position in shares of Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 414 shares during the period. Allworth Financial LP boosted its position in shares of Royalty Pharma by 41.6% during the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 452 shares during the period. Westpac Banking Corp purchased a new position in shares of Royalty Pharma during the fourth quarter worth $53,000. Finally, National Bank of Canada FI boosted its position in shares of Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 371 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Performance

Shares of RPRX traded up $0.12 during midday trading on Friday, reaching $35.59. 2,020,693 shares of the stock were exchanged, compared to its average volume of 3,712,651. The business's 50-day moving average price is $34.49 and its 200 day moving average price is $32.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $36.89. The company has a market capitalization of $20.01 billion, a price-to-earnings ratio of 19.24, a PEG ratio of 2.37 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. The firm had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. On average, sell-side analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.47%. Royalty Pharma's payout ratio is 47.57%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Morgan Stanley set a $54.00 price target on Royalty Pharma and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, Wall Street Zen cut Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $48.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.